Systematic Review on the Efficacy and Safety of Erenumab for the Prevention of Migraine
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: This study aimed to provide efficacy and safety information on the use of erenumab for prevention of episodic and chronic migraines. Methods: The keywords “Erenumab and migraine” were used to search the PubMed database to then compile efficacy and safety data for erenumab. Data from relevant Phase 2 and Phase 3 clinical trials were analyzed, using RevMan for statistical analysis. Results: Three clinical trials (one Phase 2 and two Phase 3 studies) were retrieved. All three trials used the same primary endpoint (change from baseline in monthly migraine days (CBMD)) to evaluate efficacy and safety of erenumab use for prevention of episodic and chronic migraines. Subcutaneous doses of erenumab (70 or 140 mg) were administered monthly in each trial, for 3 months (Studies 2, and 3) or 6 months (Study 1). The mean differences in CBMD in the 70 mg and 140 mg erenumab arms were -1.36 and -1.98, respectively, compared to that in the placebo arm. Some adverse events, such as nasopharyngitis and upper respiratory tract infection, were reported, but no differences in safety between erenumab and placebo were found to be significant. Conclusions: Erenumab showed superior efficacy in prevention of migraines compared to placebo. However, additional information regarding the long-term safety of erenumab should be collected. Therefore, post-marketing surveillance for adverse events is needed.
Abstract
Objective: This study aimed to provide efficacy and safety information on the use of erenumab for prevention of episodic and chronic migraines. Methods: The keywords “Erenumab and migraine” were used to search the PubMed database to then compile efficacy and safety data for erenumab. Data from relevant Phase 2 and Phase 3 clinical trials were analyzed, using RevMan for statistical analysis. Results: Three clinical trials (one Phase 2 and two Phase 3 studies) were retrieved. All three trials used the same primary endpoint (change from baseline in monthly migraine days (CBMD)) to evaluate efficacy and safety of erenumab use for prevention of episodic and chronic migraines. Subcutaneous doses of erenumab (70 or 140 mg) were administered monthly in each trial, for 3 months (Studies 2, and 3) or 6 months (Study 1). The mean differences in CBMD in the 70 mg and 140 mg erenumab arms were -1.36 and -1.98, respectively, compared to that in the placebo arm. Some adverse events, such as nasopharyngitis and upper respiratory tract infection, were reported, but no differences in safety between erenumab and placebo were found to be significant. Conclusions: Erenumab showed superior efficacy in prevention of migraines compared to placebo. However, additional information regarding the long-term safety of erenumab should be collected. Therefore, post-marketing surveillance for adverse events is needed.
참고문헌 (19)
- Stovner L, "The global burden of headache:a documentation of headache prevalence and disability worldwide", Cephalalgia, 27(3), pp.193~210 (2007)
- Lipton RB, "A comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) study and American Migraine Prevalence and Prevention (AMPP) study:demographics and headache-related disability", Headache, 56(8), pp.1280~1289 (2016)
- Buse DC, "Chronic migraine prevalence, disability, and sociodemographic factors: results from the american migraine prevalence and prevention study", Headache, 52(10), pp.1456~1470 (2012)
- Headache classification committee of the International Headache Society, "The international classification of headache disorders, 3rd edition (beta version)", Cephalalgia, 33(9), pp.629~808 (2013)
- "Management of migraine (with or wihout aura)"[URL]
- Raffaelli B, "The biology of monoclonal antibodies:focus on calcitonin gene-related peptide for prophylactic migraine therapy", Neurotherapeutics, 15(2), pp.324~335 (2018)
- Giamberardino MA, "Calcitonin generelated peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab", J Pain Res, 10, pp.2751~2760 (2017)
- Tepper SJ, "History and review of anti-Calcitonin Gene-Related Peptide(CGRP) Therapies: from translational research to treatment", Headache, 58(Suppl 3), pp.238~275 (2018)
- "News and events"[URL]
- Edvinsson L, "CGRP as the target of new migraine therapies-successful translation from bench to clinic", Nat Rev Neurol, 14(6), pp.338~350 (2018)
- Taylor FR, "Antigens and antibodies in disease with specifics about CGRP immunology", Headache, 58(Suppl 3), pp.230~237 (2018)
- Yuan H, "CGRP monoclonal antibodies for migraine: rationale and progress", BioDrugs, 31(6), pp.487~501 (2017)
- Bigal ME, "Monoclonal antibodies for migraine:preventing calcitonin gene-related peptide activity", CNS Drugs, 28(5), pp.389~399 (2014)
- Goadsby PJ, "A controlled trial of erenumab for episodic migraine", N Engl J Med, 377(22), pp.2123~2132 (2017)
- Dodick DW, "ARISE: A Phase 3randomized trial of erenumab for episodic migraine", Cephalalgia, 38(6), pp.1026~1037 (2018)
- Tepper S, "Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial", Lancet Neurol, 16(6), pp.425~434 (2017)
- "Clinicaltrials.gov (NCT02456740)"[URL]
- "Clinicaltrials.gov (NCT02483585)"[URL]
- "Clinicaltrials.gov (NCT02066415)"[URL]